KCT0004202尚未招募未知
Phase 2 study of Daratumumab in combination with Thalidomide and Dexamethasone in relapsed or refractory Myeloma
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •? Multiple myeloma, diagnosed according to standard criteria of International Myeloma Workshop, with relapsing and refractory disease after the last treatment at study entry
- •? Males and females = 18 years of age
- •? Patients must have evaluable multiple myeloma with at least one of the following (within 21 days of starting treatment)
- •- Serum M-protein = 0.5g/dL,
- •- Urine M-protein = 200mg/24 hour,
- •- In subjects without detectable serum M-protein, Urine M-protein, or serum free light chai = 100mg/L (involved light chain) and an abnormal kappa/Lambda ratio
- •? Must receive at least 1 line but does not exceed 6th of prior treatment. (Induction therapy followed by stem cell transplantation and consolidation/maintenance therapy will be considered as one line of treatment)
- •? Must have relapsed disease and/or be refractory to prior treatment except for thalidomide or lenalidomide. Refractoriness is defined as disease progression on treatment or progression within 6 months after the last dose of a given therapy. Relapse is defined according to the criteria of International Myeloma Workshop.
- •? Eastern Cooperative Oncology Group Performance Status of 0 to 2
- •? Patients must meet the following clinical laboratory criteria with 21 days of starting treatment.
- •- Absolute neutrophil count = 1,000/mm3 and platelet = 50,000/mm3 (= 30,000/mm3 if myeloma involvement in the bone marrow is >50%)
- •- Total bilirubin = 1.5 x the upper limit of the normal range. Alanine aminotransferase and aspartate aminotransferase = 3 x the upper limit of the normal range.
- •- Calculated or measured on the basis of a standard formula, such as Cockcroft and Gault creatinine clearance = 30mL/minute
- •? Female patients who:
- •- Are naturally postmenopausal or surgically sterile for at least 2 year before enrolment
- •- All female of childbearing potential must have two negative pregnancy test within 10-14 days and 24hrs before commencing thalidomide. Female of childbearing potential must agree to use two reliable methods of contraception simultaneously or practice complete abstinence from any heterosexual intercourse during the following time periods related to this study: for at least 28 days before starting study ; while participating in the study; for at least 28 days after last daratumumab dosing or for 6 months after last thalidomide doging.
- •? Male patients, even if surgically sterilized (i.e. status post-vasectomy), who agree to practice effective barrier contraception during the entire study treatment period and through 28 days after the last dose of study treatment and agree to not donate sperm at all the time.
- •? Written informed consent in accordance with federal, local and institutional guidelines
排除标准
- •1) Female patients who are lactating or pregnant
- •2) Multiple Myeloma of Immunoglobulin M subtype
- •3) Glucocorticoid therapy (prednisolone > 30mg/day or equivalent) within 14 days prior to informed consent obtained
- •4) Polyneuropathy/Organomegaly/Endocrinoapthy/Monoclonal gammopathy or M proteins/Skin defects(POEMS) syndrome
- •5) Plasma cell leukemia or circulating plasma cells > 2.0 x 109/L
- •6) Waldenstrom’s Macroglobulinaemia
- •7) Existing peripheral neuropathy of grade 2 or higher or presence of neuropathic pain within 14 days prior to informed consent obtained
- •8) Patients with known amyloidosis or myelodysplastic syndrome
- •9) Chemotherapy with approved or investigation anticancer therapeutics within 21 days prior to starting this study.
- •10) Focal radiation therapy within 7 days prior to start of this study. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to start of Daratumumab.
- •11) Patients who have received immunotherapy (except steroids) and biotoxin that are likely to be active within 21 days of the start of treatment for this clinical trial
- •12) Major surgery (excluding kyphoplasty) within 28 days prior to start of this study.
- •13) Active congestive heart failure (New York Heart Association Class 3 or 4), symptomatic ischaemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within 4 months prior to informed consent obtained.
- •14) Patients to human immunodeficiency virus infection, hepatitis C (acute hepatitis C reaching continuous viral response after antiviral treatment), or active infection requiring antiviral, anti-bacterial agents, including test subjects known as serum-positive (defined as positive examination of hepatitis B surface antigen) for hepatitis B. Subjects with resolved infection (ie, subjects who are hepatitis B surface antigen negative but positive for antibodies to hepatitis B core antigen and/or antibodies to hepatitis B surface antigen) must be screened using realtime polymerase chain reaction measurement of hepatitis B virus deoxyribonucleic acid levels. Those who are polymerase chain reaction positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of hepatitis B virus vaccination (antibodies to hepatitis B surface antigen positivity as the only serologic marker) AND a known history of prior hepatitis B virus vaccination, do not need to be tested for hepatitis B virus deoxyribonucleic acid by polymerase chain reaction.
- •15) Patients with known arteriosclerosis
- •16) Patients with creatinine clearance <30mL/minute
- •17) Second malignancy within the past 3 years except:
- •- Adequately treated basal cell or squamous cell skin cancer
- •- Carcinoma in situ of the cervix
- •- Breast carcinoma in situ with full surgical resection
- •18) Patients with steroid or thalidomide hypersensitivity
- •19) Patients previously treated with daratumumab or other anti-CD38 antibodies.
- •20) Ongoing graft-versus-host disease
- •21) Disease refractory to thalidomide or lenalidomide
- •22) Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to starting this study
- •23) Any clinically significant medical disease or psychiatric condition that, in the investigator’s opinion, may interfere with protocol adherence or a patient’s ability to give informed consent.
- •24) Patients with known allergies, overreaction or resistance to monoclonal antibodies, human proteins or their subcom
研究者
相似试验
尚未招募
不适用
A phase II study of daratumumab in combination with bortezomib and dexamethasone in patients with multiple myeloma who received 1 prior line of therapyKCT0004352Samsung Medical Center26
进行中（未招募）
不适用
A Phase 2 Study of Daratumumab in Combination with Lenalidomide, Bortezomib and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients eligible for ASCTKCT0006549Samsung Medical Center26
尚未招募
不适用
Phase 2 study of Daratumumab in combination with bortezomib and dexamethasone in newly diagnosed multiple myelomaDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0005839Seoul National University Hospital63
进行中（未招募）
1 期
A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) AmyloidosisEUCTR2021-002639-48-ESJanssen-Cilag International N.V.150
进行中（未招募）
1 期
A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) AmyloidosisEUCTR2021-002639-48-NLJanssen-Cilag International N.V.150